Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response

D A Cameron, W M Gregory, A Bowman, E D Anderson, P Levack, P Forouhi, R C Leonard

Research output: Contribution to journalArticlepeer-review

Abstract

Although clinical response to primary chemotherapy in stage II and III breast cancer is associated with a survival advantage, it is the degree of pathological response in the breast and ipsilateral axilla that best identifies patients with a good long-term outcome. A mathematical model of the initial response of 39 locally advanced tumours to anthracycline-based primary chemotherapy has been previously shown to predict subsequent clinical tumour size. This model allows for the possibility of primary resistant disease, the presence of which should therefore be associated with a worse outcome. This study reports the application of this model to an additional five patients with locally advanced breast cancer, as well as to 63 patients with operable breast cancer, and confirms the biological reality of the model parameters for these 100 breast cancers treated with primary anthracycline-based chemotherapy. The tumours that responded to chemotherapy had higher cell-kill (P
Original languageEnglish
Pages (from-to)98-103
Number of pages6
JournalBritish Journal of Cancer
Volume83
Issue number1
DOIs
Publication statusPublished - Jul 2000

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Axilla
  • Breast Neoplasms
  • Carcinoma
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Combined Modality Therapy
  • Cyclophosphamide
  • Doxorubicin
  • Drug Resistance, Neoplasm
  • Estrogens
  • Female
  • Fluorouracil
  • Humans
  • Lymphatic Metastasis
  • Mastectomy
  • Models, Biological
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Neoplasms, Hormone-Dependent
  • Prednisolone
  • Prognosis
  • Radioisotope Teletherapy
  • Survival Analysis
  • Survivors
  • Treatment Outcome
  • Vincristine

Fingerprint

Dive into the research topics of 'Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response'. Together they form a unique fingerprint.

Cite this